HOSPITAL UNIVERSITARIO RUBER
Departament
Pierre and Marie Curie University
París, FranciaPublicacions en col·laboració amb investigadors/es de Pierre and Marie Curie University (3)
2021
2016
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052
2014
-
Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): An open-label, randomised phase 3 trial
The Lancet Oncology, Vol. 15, Núm. 11, pp. 1269-1278